Back to list

Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: Results from the Indonesian cohort of the A1chieve study

Pradana Soewondo a * , Dharma Lindarto b, Sony Wibisono c, Olly Renaldi d and Tjokorda Gde Dalem-Pemayun e

Diabetes Research and Clinical Practice, pages S41 - S46

Published online Aug-2013


Article view:

Abstract

Aim

To evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in Indonesian type 2 diabetes patients switched from biphasic human insulin 30 (BHI 30) as a sub-analysis of the A1chieve study.

Methods

Clinical safety and effectiveness over 24 weeks was evaluated in Indonesian patients who switched from BHI 30 to BIAsp 30 at the discretion of their physician.

Results

A total of 244 patients with mean age ± SD 55.6±9.5 years, BMI 24.6±3.8kg/m2, and mean diabetes duration 7.8±5.7 years were included. The mean pre-study BHI 30 dose was 0.56±0.25 IU/kg and the baseline BIAsp 30 dose was 0.60±0.26U/kg titrated up to 0.65±0.25 U/kg by Week 24. No serious adverse drug reactions were reported throughout the study. Overall hypoglycaemia decreased from 2.18 to 0.06 events/patient-year with a significant decrease in the proportion of patients affected (p < 0.0001). No nocturnal or major hypoglycaemia was reported at Week 24. HbA1c improved from 8.8±1.2% at baseline to 7.3±0.8% at Week 24. A total of 45 patients achieved HbA1c <7.0% as compared to 5 patients with HbA1c <7.0% at baseline. FPG and PPPG improved significantly after 24 weeks (p < 0.001). Quality of life was positively impacted (change in visual analogue scores, 3.0±11.6 points, p < 0.001).

Conclusion

Switching from BHI 30 to BIAsp 30 in this Indonesian cohort was well-tolerated and improved glycaemic control with a decreased risk of hypoglycaemia.

Keywords: Switch, Biphasic human insulin 30, Biphasic insulin aspart 30, Indonesia.


Article Outline

References

  • 1 DR Whiting, L Guariguata, C Weil, J Shaw. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-321 Crossref.
  • 2 International Diabetes Federation. IDF Diabetes Atlas. 5th edn. Brussels, Belgium; 2011, updated 14 November 2012.
  • 3 L Mihardja, Delima, HS Manz, L Ghani, S Soegondo. Prevalence and determinants of diabetes mellitus and impaired glucose tolerance in Indonesia (a part of basic health research/Riskesdas). Acta Med Indones. 2009;41(4):169-174
  • 4 A Wright, ACF Burden, RB Paisey, CA Cill, RR Holman, et al., the UK Prospective Diabetes Study Group. Sulphonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336 Crossref.
  • 5 K Niswender. Early and aggressive initiation of insulin therapy for type 2 diabetes: What is the evidence?. Clin Diab. 2009;27:60-68 Crossref.
  • 6 S Heller. Reducing hypoglycaemia with insulin analogues. Int J Obes Relat Metab Disord. 2002;26(Suppl 3):S31-S36 Crossref.
  • 7 M Evans, PM Schumm-Oraeger, J Vora, AB King. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13(8):677-684 Crossref.
  • 8 LV Jacobsen, B Sogaard, A Riis. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000;56:399-403 Crossref.
  • 9 BO Boehm, JA Vaz, L Brøndsted, PD Home. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15:496-502 Crossref.
  • 10 BO Boehm, PD Home, C Behrend, NM Kamp, A Lindholm. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19:393-399 Crossref.
  • 11 JA Davidson, A Liebl, JS Christiansen, G Fulcher, RJ Ligthelm, P Brown, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clin Ther. 2009;31:1641-1651 Crossref.
  • 12 M Velojic-Golubovic, D Mikic, M Pesic, D Dimic, S Radenkovic, S Antic. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endocrinol Invest. 2009;32:23-27 Crossref.
  • 13 I Schmoelzer, A de Campo, H Pressl, H Stelzl, P Dittrich, K Oettl, et al. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2005;113:176-181 Crossref.
  • 14 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94:352-363 Abstract, Full-text, PDF, Crossref.
  • 15 S Shah, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al., on behalf of the IMPROVE Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract. 2009;63:574-582 Crossref.
  • 16 M Shestakova, SK Sharma, M Almustafa, KW Min, N Ayad, ST Azar, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23(12):3209-3214 Crossref.
  • 17 E Paz-Pacheco. Diabetes Clinical Practice Guidelines (CPGs) for the ASEAN region: Country initiatives for collectively enhanced diabetes care in the region. JAFES. 2011;26(1):36-37 Crossref.
  • 18 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596 Crossref.
  • 19 PG McNally, JD Dean, AD Morris, PD Wilkinson, G Compion, SR Heller. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30:1044-1048 Crossref.
  • 20 NK El Naggar, P Soewondo, ME Khamseh, J Chen, J Haddad. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study. Diabetes Res Clin Pract. 2012;98(3):408-413
  • 21 JP Vandenbroucke. What is the best evidence for determining harms of medical treatment?. CMAJ. 2006;174(5):645-646 Crossref.

Footnotes

a University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia

b Division of Endocrine Metabolic, Department of Internal Medicine, H Adam Malik Hospital, Medan, Indonesia Division of Endocrine Metabolic, Department of Internal Medicine, H Adam Malik Hospital, Medan, Indonesia

c Diabetes and Nutrition Centre, Dr. Soetomo Hospital, School of Medicine Airlangga University, Surabaya, Indonesia Diabetes and Nutrition Centre, Dr. Soetomo Hospital, School of Medicine Airlangga University, Surabaya, Indonesia

d Mitra Bekasi Barat Hospital, Bekasi, Indonesia Mitra Bekasi Barat Hospital, Bekasi, Indonesia

e Diponegoro University, Kariadi Hospital, Semarang, Indonesia Diponegoro University, Kariadi Hospital, Semarang, Indonesia

* Corresponding author at: Sp-PD-KEMO, Division of Endorinology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia. Tel.: +62 21 390 7703; fax: +62 21 392 8659

Back to list